emerging animal health company apac showcase: presenter ...€¦ · company apac showcase:...

19th-20th October, 2016 · Grand Hyatt Hong Kong

2016 EMERGING ANIMAL HEALTH COMPANY APAC SHOWCASE:

PRESENTER PROFILES

Kisaco Research is proud to announce the 12 companies selected to present at the Animal Health Investment Asia

Forum Emerging Company Showcase.

Visit www.animalhealthasia.com for more information

Presents the...

Farbe/colour:PANTONE 288 CV

Headline Sponsor Sponsors

ABOUT THE EMERGING COMPANY SHOWCASE

Key to the value the Animal Health Investment Asia Forum is the Emerging Company Showcase – delivering value in two distinct ways. Our Selection Committee selected from the list of applicants a list of twelve emerging companiesto present to our audience. These presentations will showcase the innovation and opportunity these emerging companies bring to their various markets. Secondly, this group, plus additional emerging companies that are being invited to attend, will be available to schedule 30 minute private meetings with other attendees throughout the event using our Meeting Mojo application. Interested in Joining them?

A Special Thank-You to the Selection Committee

Headline Sponsor: Sponsors:

COMPANIES

ANIMAL HEALTH INVESTMENTASIA FORUM

ANIMAL HEALTH INVESTMENT ASIA FORUM 12 SELECTED EMERGING COMPANY PRESENTERS 2Farbe/colour:PANTONE 288 CV

Register today

Tony ZiLong Tan Founder and Managing Partner Z-LINK BIOTECH

Pieter JK Brouwer Ice Cold Bright Sun Int BVBA

Frank-Christian Raffel Managing Director MELCHERSRAFFEL Ltd

Charles Hoare Managing Director, Head of European Healthcare STIFEL

Paul Dick President VET VENTURE CAPITAL

Ronan Molloy President INNOVATION STOCKYARD

Michael Hemprich Head of Business Development IDT BIOLOGIKA

Claude Kaplan Head of IP Management and Commercialization BENCHMARK HOLDINGS PLC

http://animalhealthasia.com/register/pricing

Da Bei Nong (DBN) Animal Medicine Research Center is a subsidiary of DBN Group. We are dedicated to research, development, manufacturing and commercialization of novel animal health products. We have nearly 100 highly qualified personnel in the Center. We have state of the art laboratory facility and instruments with total investment of more than 60 million RMB. We are capable of conducting diagnostic and vaccine development work all kinds of animal diseases. Till 2016, our Center has completed numerous technology out-licensing deals in a total value of 300 million RMB which is by far the most productive animal vaccine R&D Center in China. We are one of the largest commercialized vaccine research and diagnostic test units for swine disease in China.

Our center focuses on swine and canine disease prevention and control. We have 24 ongoing R&D projects and have received 5 National New Veterinary Certificates for innovative vaccines. In 2011, the “PCV2 Vaccine, Inactivated (DBN-SX07 strain)” developed by our Center won the National 1st Class State Science & Technology Progress Award. Our canine CDV-CPV combo attenuated vaccine, canine CDV-CPV-RV trivalent vaccine, canine CDV-CPV-CAV-CPIV-RV pentavalent vaccine will be approved within the next 1 - 2 years. Our Molecular Biology Department is fully capable of developing recombinant and subunit vaccines. Our Diagnostic Department is supported by thousands technical service personnel who provide disease information and field isolates to the Center. This enables the Center to obtain the most relevant strains for vaccine development.

We strive to be the best contract research organization (CRO) for international animal health companies. With our insight knowledge in animal diseases in China, full collection of field isolates and a dedicated R&D team, we are capable of developing animal vaccines in relative short time. In fact we have a number of vaccine technology ready for licensing-out. We are striving for continuous improvement in our performance by digging into the industrial potentials and creating a first class global R&D organization.

One achievement in the Animal Health space:Our PCV2 vaccine won the First Class State Science & Technology Progress Award. DBN is the first animal health company who receive such honor. and we has completed numerous technology out-licensing deals (RMB 300 million) which makes us by far the most productive animal vaccine R&D Center in China.

Biggest opportunity in the Animal Health industry?Our new R&D facility (56,000 M2) in the Daxing Biomedical Industrial Base in Beijing is nearly complete and has vaccine research laboratories, animal housing, and a pilot plant. Phase 1 of the vaccine plant is 13,000 M2 with 11 production lines and over 100 staff. With our strong R&D team, we can deliver top-class innovative products.

One thing we aim to change and/or improve the Animal Health industry? One of our focus areas is to develop safe and efficacious vaccines for eradication of zoonotic diseases. Such an approach is consistent with the government’s “Long-term National Animal Disease Prevention and Control planning (2012-2020)” strategy.

Dr. Zhao YarongGeneral Manager, Animal Medicine Research Center

ANIMAL HEALTH INVESTMENT ASIA FORUM 12 SELECTED EMERGING COMPANY PRESENTERS 3

Emerging Company Profiles COMPANIES


About the Speaker:Professor Yarong ZHAO received his Ph.D. in Veterinary Parasitology from the China Agricultural University in 1993. His research area was in cryptosporidiosis and he received the First Class Science & Technology Award from the Chinese Ministry of Agriculture in 1993. From 1993 to 1998, he worked as National Technical Manager in Bayer Animal Health China. Later, he worked in Fort Dodge Animal Health and Schering-Plough China as Regulatory and Technical Manager. In 2003, he was appointed as General Manager of the Animal Medicine Research Center of the Dabeinong (DBN) Group, an innovative R&D center with a focus on disease diagnosis, vaccine development and technology transfer. He has published 51 scientific papers. Inactivated porcine circovirus type 2 (PCV2) vaccines, developed by a team led by Prof. Zhao, won the First Class State Science & Technology Progress Award in 2012. The Center has obtained five National Veterinary New Drug Certificates and licensed out a number of technologies to other animal health companies with a total transaction value of approximately RMB 300 million.

Sinovet (Beijing) Biotechnology Co., Ltd is an animal health company dedicated to the development, manufacturing, and marketing of animal biological products. Product profiles cover major animal species, especially for swine, cattle, and companion animals. The company has more than 200 full-time employees conducting research and development, manufacture, and marketing. There are more than 20 active research projects in different development stages and five new veterinary drug licenses have been approved in last 5 years. A modern manufacture plant of 5 production lines with modern equipment are fully accredited by Chinese authority to produce live and killed viral and bacterial vaccines. • Strong R&D team with successful license experience • Unique product profiles for China and global countries, such as double gene-deleted

HP PRRS vaccine, and HP PRRS/CSF-PRRS combo vaccines which clearly differentiate from the existing products

• Technologies: Suspension culture system, heat-stable stabilizers for lyophilization, vaccine seed development and selection, and genetic engineering technology

• Fully accredited manufacture facility with five product lines and capability to produce live and killed viral and bacterial products.

• Regulatory Affairs Team has a plenty of experience in product registration in China, US, and European countries.

• Full access to local resources including clinical disease information and clinical samples and understood the need for local markets and farms.

One achievement in the Animal Health space:We have successfully developed a PRRS-CSF combo vaccine, the first PRRS-CSF combo vaccine in the world. The product is highly recognized in China and global markets.

Biggest opportunity in the Animal Health industry?China has a half of the world’s pig population. Any safe and efficacious products, either biologicals and pharmaceuticals, tackling major swine diseases will bring the biggest opportunity for animal health industry in China.

One thing we aim to change and/or improve the Animal Health industry? New product registration process in some Asian countries including China and Japan are very lengthy, which has negative impact on prevention and control of emerging diseases.

Dr. Shucheng ZhangVice-president

“China has a half of the world’s pig population. Any safe and efficacious products, either biologicals and pharmaceuticals, tackling major

swine diseases will bring the biggest opportunity for animal health industry in China.”


About the Speaker:Dr. Shucheng Zhang, Vice President of Sinovet (Beijing) Biotechnology Co. Ltd., in charge of R&D and manufacturing.

Received his Bachelor of Veterinary Medicine from Shenyang Agricultural University, Master’s Degree in Veterinary Microbiology from the University of Surrey, UK, and Ph.D. in Virology from Kansas State University

A Research Scientist, Project Leader, and Associate Director of Swine Disease Research at the Harbin Veterinary Research Institute, China for 10 years, successfully developed several swine bacterial oil adjuvant vaccines.

A Senior Research Scientist, Project Leader, and Group Leader at Intervet Inc. (Merck/MSD) in the USA, had focused on companion animal/equine vaccine research development and led the research team and licensed 7 new equine vaccines including West Nile Virus live chimera vaccine.

As a China R&D leader for Pfizer Animal Health/Zoetis，Dr. Zhang established the Zoetis R&D team and local biological product program in China. Identified and licensed first local vaccine product (high pathogenic PRRSV) for Zoetis Joint-Venture business.



Phagelux is a platform company that utilizes phages, lysins and similar technologies to develop adjuncts or alternatives to antibiotics in the fields of agri health and human health.

The AgriHealth division of Phagelux has R&D labs in both North America and China and has a 30,000 SF factory in Salt Lake City and also a scale-up facility in Suzhou. In addition, a larger GMP standard manufacturing facility is planned. This new facility in Wuhan is anticipated to start production by the end of 2017.

At present, the AgriHealth group has 2 crop products on the market (these products are both preventative and curative) and two other products that have already received regulatory approvals. The products with regulatory approvals will be launched in late 2016 or early 2017. The recently approved products are for: (1) the prevention of salmonella during the processing of meats (initially just approved by FDA for sale for the processing of chicken parts) and (2) for the prevention of EMS/APHNS. In addition, there are another 9 products in the pipeline in the AgriHealth division. These new products are primarily phage-based products for the prevention or treatment of animal diseases.

Key Advantages of Phagelux include:• Large and experienced development teams • Strong delivery technologies, particularly in terms of: (1) affixing phages and lysins to

multiple surfaces and (2) creating novel sustained release delivery systems• Strong partnering capabilities• Experienced product oriented management

Existing investors include WuXi AppTec and Fosun.

One achievement in the Animal Health space:Phagelux is the first company to be ready to come to market with a treatment for EMS/APHNS. This disease currently kills hundreds of millions of dollars of shrimp and is very difficult to treat using current treatment options. Importantly, from start of development to market entry was completed in two years including field trials.

Biggest opportunity in the Animal Health industry?Government and industries worldwide are looking for treatment alternatives that are safer than antibiotics while at the same time being equally as effective. The technologies utilized and created by Phagelux appear capable of meeting these needs without increasing costs to end users.

One thing we aim to change and/or improve the Animal Health industry? Phagelux aims to reduce the use of antibiotics across multiple fields.

Mark EngelCEO

“Government and industries worldwide are looking for treatment alternatives that are safer than antibiotics while at the same time being

equally as effective. Phagelux appears to be capable of meeting these needs without increasing costs to end users.”


About the Speaker:Mark has been building multi-national oriented life sciences companies in China since 1990. Mark’s most recent start-up is Phagelux.

Mark is also the co-founder and director of Haoyisheng (“Good Doctor”) which is a leading Chinese professional healthcare information, education, database/software and connected medicine group company.

Previously built companies include: (1) NPO Pharmaceuticals (sold in 1999), at the time a leading “multinational” pharma organization in China; (2) TPNT (sold to partner in 2008), a formulation and development company; (3) Excel PharmaStudies (sold in late 2009 to PPD), at the time the largest clinical research organization (CRO) in China and with additional operations throughout Asia; and (4) Tiger Medical Group (merged with ASP in 2013), a manufacturer and exporter of about 600 medical and disposable products from Asia to institutional buyers worldwide (primarily US).

Mark is also the Managing Director of Tianshi Capital which is an angel investor in China life sciences start-up companies including in the fields of: (1) animal vaccines; (2) medical devices and (3) agri/aquaculture technologies.



Nuovo Biologics, LLC is a biotechnology company located in South Florida, USA, focused on developing peptide，based therapeutics for the veterinary and human markets to treat viral diseases. Viral pathogens pose a serious threat to both animals and humans, and there are relatively few therapeutics or prophylactics available for these biologic threats. Each year, viral diseases kill or incapacitate millions of animals and people world，wide. Moreover, emerging viral pathogens, such as Mers CoV, Ebola, Zika and Chikungunya viruses are becoming an ever，increasing threat world-wide. While many drugs exist for treating bacterial infections, few antiviral drugs exist in the human market, and there are currently no FDA approved antiviral agents for use in animals.

Most antiviral therapeutics marketed for human viral disease are virus specific, and are prone to resistance if the virus mutates. Similarly, vaccines are also virus specific, and become increasingly less effective as the target antigen changes due to mutation, potentially losing all efficacy. There are no broad spectrum antiviral therapeutics commercially available. Interferons are the closest agents available, but are costly, and can exhibit serious adverse events.

Our Company embraces the ‘One Health’ model, but is unique in applying this concept to product development. Over 60% of infectious disease in humans originates from animals, known as zoonosis. One Health recognizes the intimate links between animal and human health, and the need to integrate multiple disciplines in an effort to address zoonotic viral diseases.

Consequently, Nuovo Biologics is first focused on animal health in order to specifically design a research, development and commercialization model to be translational for human product development, creating a faster path to market, and generating revenue for reinvestment during the process. Using the ‘One Health’ approach, which recognizes the linkages between animal and human health, Nuovo Biologics is positioned for future growth in both the animal and human markets.

Nuovo Biologics has implemented a unique business model leveraging cooperation with colleagues in academic and private organizations to bring the best thought leaders to bear on the research and development phase of this effort. Since inception, Nuovo has been given two INAD (Investigational New Animal Drug) numbers by the FDA, been issued several patents, developed a cGMP-like manufacturing process, and performed multiple successful pilot clinical studies, primarily for companion animal viral upper respiratory disease indications.

Jeff FisherChairman


About the Speaker:As Chairman of Nuovo Biologics, LLC, Mr. Fisher is responsible for oversight of strategic business acquisitions as well as business opportunities with key accounts. Previously he was the COO of Acaria Health, a position he held from January 1, 2011 through 8 months post sale to Centene Corporation on April 1, 2013. He served as EVP of Business Development for Acaria Health, Inc. as of January 1, 2014.

Previously, he was the President and CEO of Fisherx Consulting, LLC from October 2006 to December 2010. In addition, Mr. Fisher was VP of Purchasing and Manufacturer Relations for MedMark, Inc. from October 2003 up until its sale to Walgreens in September 30, 2006.

He was President and CEO of Fisher’s SPS, Inc. since its formation in 1998 up until its sale in October 2003 to MedMark, Inc. Also, from 1991 up until its sale on June 1, 2004 to Care Capital Management, Mr. Fisher was the Founder, President and CEO of Fisher’s Pharmacy. Mr. Fisher was also a founding member and served on the Board or Directors of Three Rivers Pharmaceuticals, LLC, a privately held pharmaceutical drug manufacturing company, from April of 2000 up until its sale to Kadmon Pharmaceuticals in October 2010. In March of 2006 Mr. Fisher became a principle and board member for Creehan and Co., a nationally based Healthcare IT company. Mr. Fisher received his Bachelor of Science Degree in Pharmacy from Duquesne University in 1985.

In 2006 Mr. Fisher was awarded the prestigious Ernst and Young Entrepreneur of the Year in Health and Life Sciences for Upstate New York and Western Pennsylvania. Mr. Fisher currently serves on the Duquesne University School of Pharmacy curriculum and planning board, and in 2005 he was awarded the Duquesne University School of Pharmacy Distinguished Alumni Award.



One achievement in the Animal Health space:Our new antiviral drug for viral upper respiratory infections demonstrated a significant survival rate and resolution of clinical symptoms in a large canine distemper disease pilot study. In areas where the incidence of this untreatable disease pose a public health hazard the potential impact of our drug can be immense.

Biggest opportunity in the Animal Health industry?As viral disease poses a serious threat to animals, development of antiviral drugs for both companion and production animals is a significant opportunity for the animal health Industry. Vaccines only act as preventative measures, not as a therapeutic, and current vaccines only provide prophylaxis to a limited set of viruses.

One thing we aim to change and/or improve the Animal Health industry? Evolving the “One Health” concept into a practical business approach offers a new path for improving global health. Separation of animal and human product development today does not take sufficient advantage of the linkages that can be leveraged to develop better medical models that effectively cross zoonotic barriers.

ARETEON PTE. LTD was incorporated in 2011, to fill-up a critical gap bridging research institutions with early-stage technologies, and animal health companies that constantly demand innovative, cost-effective, safe and efficacious veterinary therapeutics.

It searches and license-in fundamental technologies with a potentially strong application in the veterinary market from research institutes around the world. The Company then transforms these fundamental technologies into OTC and veterinary prescription-only medicine through collaborations with downstream contract research organisations (CROs) on the clinical aspects of the development. This transformation also includes in-house development of manufacturing and quality control SOPs, so as to be able to offer stable, good quality and standardized active principal ingredients to animal health companies as well as formulation of branded therapeutic solutions for the companion animal market.

One of the most important industry concerns in the veterinary field today is the lack of non-bacterial-resistant, safe and efficacious antimicrobial drugs for both livestock and canine-feline market segments. The market size of Veterinary Antimicrobials for Therapeutic Use in 2010 is US$ 2,900 million with a CAGR of 8% in the next 5 years (Vetnosis 2010 annual report). East Asia has 18% share of this product category segment. It can be further divided into:1. Dog and cat antimicrobial therapy = US$ 1,190 million, of which topical therapeutic applications

constitute one-third of this value with the fastest growth rate.2. Cattle and sheep antimicrobial therapy = US$ 860 million.3. Pig antimicrobial therapy = US$ 520 million.4. Poultry antimicrobial therapy = US$ 320 million. In 2015, Areteon successfully produced a unique API which is both antimicrobial and anti-fungal without drug resistance for veterinary use. It disrupts the microbes’ membranes without the need to enter inside the microbe and safer in prolonged contact with mammalian tissues at the same time biocompatible.

Based on this newly-patented and novel poly-cationic polymer, the development work is currently focused on topic solutions for companion animals, and can be extended to other forms of therapeutic applications. The plan is to launch 3 skin-care products in Q4 2016.

One achievement in the Animal Health space:The chemical synthesis reported in the patents is a laboratory-scale process. The optimization of DMDC was finalized in June 2015 and achieved savings of over 10 times in the BOM. There is a marked improvement in its yield and MIC99 value, while enhanced the synthesis away from the original SOP.

Biggest opportunity in the Animal Health industry?Drug resistant microbial is one of the hottest subjects of the 21st century. With the potential to cause nearly $100 trillion in damage to the world health and economy, the issue of infections untreatable by modern antibiotics is one that leaves many concerned and looking for solutions.

One thing we aim to change and/or improve the Animal Health industry? The top 10 animal health companies, in terms of revenue, are either European or American. Together, they occupy more than 70% of the global animal health market. These companies focus mainly on technologies from their home ground, due to cultural and linguistic constraints. Areteon offers an alternative Singapore value-proposition.

Robin LowCEO/Founder

“Drug resistant microbial is one of the hottest subjects of the 21st century. The issue of infections untreatable by modern antibiotics is one that leaves many concerned and looking for solutions.”


About the Speaker:Throughout his 40 plus years’ career, Mr. Low has been an experienced serial technopreneur and industry veteran holding senior management positions in electronics, distribution, biotechnology, eco-city development and solar energy.

His domain expertise is in turn-key project management, emerging business deal development, early stage discovery of innovative technologies including commercialization, international sales and brand marketing. Since 1982, he had established a global network of excellent business connections. He was the principal investigator for the research and development of Concentrator Photovoltaic Solar panel, wireless-speakers, and MP3 sanitary wares (INAX Japan), disruptive antimicrobial for veterinary medicine.

Currently he serves on the Panel of the Technology Enterprise Commercialization Scheme (TECS) of Spring Singapore. In addition, he also served as a Council Member of the Singapore-Zhejiang Economic and Trade Council from 2010 to 2015 promoting direct investments between Singapore and Zhejiang. On December 8th 2011, he was appointed as Senior Advisor to the Hangzhou Qianjiang Economic Development Zone Management Committee.

From 1990 onwards, he founded and mentored various companies that specialize in animal health, veterinary education, anti-microbial API without drug resistance for therapeutic use, micro-algae, renewable energy and electronics. In respect to his many years of active business participation in China, he has built up an extensive network of excellent contacts and established good working relationship with the government, universities, research institutes, and private sector.



Ridgeway Biologicals Ltd is an SME with 23 employees and supports customers throughout the United Kingdom and the EU. Through rapid innovative responses we lead the fight against evolving infectious agents that threaten animal health. Our aim is to enable the effective control of infectious diseases leading to improved animal health and farm efficiency through bespoke vaccine interventions. For farms suffering from disease outbreaks we supply bespoke (autogenous) vaccines for disease control. Unlike mass-produced vaccines our products are formulated to the specific requirements of the animals on farm. By working closely with our clients and exploiting DNA-based molecular diagnostics we strive to fully understand infectious disease problems enabling us to design effective solutions against a wide range of pathogens. Through continued monitoring of disease status on farm we can re-formulate vaccines as necessary thereby providing ongoing disease control.

The market (pigs, poultry, ruminants and aquaculture) continues to develop with a number of key factors driving growth. Bacteria and viruses are continuously evolving resulting in new disease epidemics and conventional vaccine breakdowns. As fully licensed vaccines are not always available, especially for minor farmed species, and new fully licensed products take years to develop, autogenous vaccines can provide a rapid solution and reduce dependence on antibiotics. Reducing antibiotic interventions is a market driver with legislation increasingly restricting antibiotic usage on farm and public awareness of the negative aspects of antibiotics becoming more main stream.

We have a highly adaptable vaccine manufacturing facility, which is licensed by the UK Government’s Veterinary Medicines Directorate, and enables us to supply high quality bespoke vaccines at short notice, on time and at a cost effective price. We continuously look to exploit new emerging disease threats by developing new products. To do this we have robust production processes all managed by our quality system. We have recently developed and launched a bespoke scheduling system. The system relies on a Bill of Materials specific to each customer order, which lists the antigens in the finished vaccine. Linked to this is a routing, which allows the system to schedule the entire process right through from order confirmation to dispatch of finished vaccine product. The system is able to show capacity utilization in each key part of the production process, highlighting overloads when they occur, allowing for re-scheduling to take place.

Our R&D team of three work to improve the efficiency of existing processes, develop new products and diagnostic tools.

One achievement in the Animal Health space:My research activities contributed new insights into the fundamental mechanisms by which enteric pathogens colonise and damage the gut. I am also proud to have driven the expansion of Ridgeway Biologicals to become the UK’s lead supplier of autogenous vaccines helping control infections of ruminants, pigs, poultry and farmed fish.

Biggest opportunity in the Animal Health industry?There is increasing legislation and public pressure to reduce antibiotic usage in food producing animals. Antibiotic use is driven by the lack of availability of effective vaccines against continuously evolving microbial pathogens. Autogenous vaccines can provide rapid and effective disease control avoiding recourse to antibiotics.

One thing we aim to change and/or improve the Animal Health industry? Improve animal health and welfare by better controlling infectious diseases and reduce the routine widespread use of antibiotics which threatens global food production and public health.

Tim WallisFounder and Managing Director

“Antibiotic use is driven by the lack of availability of effective vaccines against continuously evolving microbial pathogens.

Autogenous vaccines can provide rapid and e ective disease control avoiding recourse to antibiotics.”


About the Speaker:Tim has a scientific training with a BSc (Hons) in Microbiology from Leeds University and a PhD from Birmingham University for his work on Salmonella gastroenteritis. With a strong academic interest in microbial infection and immunity he spent 13 years in academia with a particular interest in the pathogenesis of Salmonella and E.coli. His work led to new insights into how these important pathogens infect food producing animals. His work is published extensively in peer reviewed scientific journals and chapters in books. After 13 years in a very fruitful research career, and after much agonizing, in 1999 he joined the family business. His entrepreneurial instincts oversaw the business expansion developing molecular diagnostics for microbial pathogens, designing novel vaccine products and associated manufacturing processes for the supply of bespoke veterinary autogenous vaccines. This through the recruitment and building of a dedicated hard working expert team and providing long lasting close customer relationships. Tim finds driving the business as equally stimulating as blue skies research. It is very exciting exploiting microbiology to characterize disease outbreaks on farm, which are causing major economic and welfare issues, and to come up with effective solutions. However his research interests are maintained by continued close links with Universities and supporting PhD students carrying out research relevant to the company needs. When not at work or meeting the demands of his wife and four daughters Tim likes to climb mountains, ride bicycles, play tennis, attend rock festivals and follow Chelsea football club.



Ringpu Bio-Technology (Ringpu) has twelve subsidiary companies with a total of nine GMP-approved manufacturing sites. Our manufacturing facilities include five for biologicals, three for veterinary pharmaceuticals, and one API plant and affiliates with 66 veterinary GMP production lines. This makes us one of the largest (in terms of volume)and one of the most diverse(in terms of product variety)manufacturing companies in China.

Ringpu follows a management philosophy that “Innovation is Our Growth Engine and We Bring Service Value to Our Customers”. We are one of only two animal health companies that are accredited as a “National Enterprise Technology Center” by five different government Ministries. Ringpu was in the first batch of National Key Laboratories accredited by the MOA. Ringpu is also a founder company for the National Veterinary Drug Industry Technology Innovation Strategic Alliance, an industry body certified by the Ministry of Science and Technology. Ringpu invests at least 10% of revenue in R&D each year. Until now, the company has received53 New Veterinary Drug Certificates, 116patents, and won the second class prize of National Science and Technology Progress in 2012.

Ringpu is strong in marketing. Our network covers 30 provinces and has established long-term cooperation with 743 large-scale breeding farms. At the same time, Ringpu continuously improves its competitiveness in the international market. For example, our products have been exported to India, Jordan, Philippines, Russia, Pakistan, and others. Ringpu has the largest companion animal hospital franchise in China with more than 100 franchise hospitals by the end of 2016. Companion animals is one of our new strategic focus areas. We believe that our efforts and capabilities will revolutionize the companion animal health segment. Currently, Ringpu has the largest pet medical chain in the domestic market and will have more than 100 chain stores by the end of 2016 – this distribution network is a key factor that will allow us to develop, revolutionize and lead the Chinese pet medicine sector.

One achievement in the Animal Health space:Ringpu initiated an industry and academic association with members from 19 leading animal health companies, 12 well-known universities and three national research institutes. This is a pilot project at the national level. The objectives are to leverage resources and current strengths to promote innovation and accelerate product development.

Biggest opportunity in the Animal Health industry?Chinese government policies are now focusing on animal health, food safety, public health and environmental protection. With over 18 billion animals, the unpredictability of major disease out breakscreates significant threats to development of livestock production. Establishment and implementation of real-time disease monitoring systems, health management practices, and“bigdata” will greatly enhance animal welfare, food safety, and economic returns.

One thing we aim to change and/or improve the Animal Health industry? Internet technology can leverage resources from veterinarians, universities, and companies to provide professional one-stop services for large-scale farms. The combined resources will greatly improve animal disease diagnosis and treatment efficiency.

Norman LeePresident


About the Speaker:• Norman Lee, Ph.D., Professor and

founder of Tianjin Ringpu Bio-Technology Co. Ltd., Director of the MOA’s Key Laboratory for Veterinary Drug Innovation, Chairman of the National Veterinary Drug Industry Strategic Alliance for Technology and Innovation, Vice-President of the Chinese Veterinary Association, President of the Tianjin Veterinary Medicine Association, post-graduate advisor at the Tianjin Agricultural University. Dr. Lee has led over 21 national, provincial, and municipal science and technology projects. He was recipient of the second prize of the National Science and Technology Progress Award and twice of the first prize of the Tianjin Science and Technology Progress Award.

• In 1998, Dr. Lee established Ringpu(Tianjin)Bio-Pharmacy Co. Ltd. And Ringpu (Baoding) Biological Pharmaceutical Co.,Ltd. He also acted as General Manager of both companies.

• In 2008, he led a management team to restructure the company and established Tianjin Ringpu Bio-Technology Co. Ltd. He was appointed Acting Chairman of the Board.

• On 17th September 2010, Tianjin Ringpu Bio-Technology Co. Ltd. was officially listed on the Shenzhen Stock Exchange and Dr. Lee is Chairman of the Board,

• In 2012, Dr. Lee was part of the research team: “Swine and poultry pathogenic bacteria resistance research and its application in development of a safe and effective new veterinary drug”. The project received the second prize of the National Science and Technology Progress Award.



Prevtec Microbia is a private Canadian biotechnology Company focused on the commercialization and development of biological products to improve animal health and increase animal production performance. The Company’s mission is to develop and market biological products as alternatives to antibiotics, to offer sustainable solutions that contribute to improving animal health, production performance and food safety.

The Company has developed a family of vaccines under the Coliprotec® brand for treating pigs against post-weaning diarrhea (“PWD”) which causes major economic loss for pig farmers.

Its first product - Coliprotec® F4 is fully developed and approved in 33 countries and is being distributed by Elanco, the animal health division of Eli Lilly in Canada and in the European Union, one of the largest market for swine biologicals (225 million pigs).

Another very large market is China’s swine production estimated at 723 million heads.

Prevtec is looking to take its first commercialized vaccine through regulatory approval in East Asia and China. The Company has established a Hong Kong subsidiary and is entertaining discussions with Asian Partners.

Prevtec has two additional developed vaccines in the Coliprotec® family (F18 and F4/F18 combined), both in marketing authorization stage for Canada and the European Union and is seeking partners for its Rest of World Distribution, namely in Asia.

The Company also has a new technology to advance to the next stage, a biological feed additive for swine production.

Prevtec Microbia has adopted a business platform that allows it, with the support of external partners, to bring a scientific discovery to commercialization, by coordinating the research stages of development, registration and manufacturing while maintaining IP connected to this discovery. This approach greatly contributes to reducing the risks associated with new product development. Prevtec Microbia is now working to repeat these steps for new products with even more agility, speed and efficiency.

One achievement in the Animal Health space:We are very proud to bring innovative biological products to the world, at a time when the global population is increasing so rapidly and needs to be fed safely. Antibiotic use is a major concern for all of us, with the increasing trend in antibiotic resistance in animals and in humans. Our Coliprotec® F4 vaccine represents a sustainable alternative to immunize pigs against the bacteria that cause PWD, reducing the use of antibiotics used to prevent or treat this disease.

Biggest opportunity in the Animal Health industry?By 2050, the world population will reach 9 billion people and they will require 100% more food. Some 70% of that increase will need to come from efficiency improving technologies. We need to be smart about improving animal health and increasing animal production performance.

One thing we aim to change and/or improve the Animal Health industry? Prevtec Microbia has adopted a business platform that allows it, with the support of external partners, to bring a scientific discovery in the Animal Health industry up to commercialization in a very agile an efficient way. Our goal is to replicate this for new biological and safe products with even more agility, speed and efficiency.

Michel FortinPresident and CEO


About the Speaker:Michel Fortin is a seasoned entrepreneur and an excellent developer and promoter, recognised for his creative strategic thinking, with a flair for identifying opportunities and raising the capital to fulfill them. Michel Fortin has exceptional negotiating skills and a track record for excellent communications in a private and public setting. Michel Fortin is CEO of Prevtec Microbia Inc. since its business start of activities in 2005, has traveled the world to expand the Company’s opportunities, has raised CDN $24 million in private equity funds and has negotiated with the largest Animal Health multinationals. It was under his leadership that Prevtec Microbia brought two innovative scientific discoveries to the commercialization stage.

Michel Fortin is a CPA and has a long experience in raising debt and equity capital, managing public and private corporations and negotiating international contracts.



Pacific GeneTech (PGT) is a commercial stage animal vaccine company that focuses on unmet needs in diseases common to animals and humans (zoonoses) and the emerging food safety vaccine market. The company owns the exclusive global rights for an innovative, patent-pending technology platform known as Aegis. Aegis generates orally administered, microbial-vectored recombinant vaccines that induce cross-protection between pathogen strains, e.g. strains of Salmonella, Campylobacter, E. coli, Eimeria and avian influenza. Pathogens mutate constantly and are hard to control and manage. Currently there are very few effective cross-protective oral vaccines for GI tract bacteria, viruses (influenza), apicomplexan parasites (e.g. Eimeria & Toxoplasma), and these also lead to human diseases. The increasing US FDA and global food recalls and tightening rules on antibiotic use in food animals are all pushing vaccine use up. Aegis vaccines provide significant cost-benefits and ease-of-use advantages over legacy vaccines. PGT also owns the exclusive, global rights to Hercules, a universal oral adjuvant/delivery system, highly effective in boosting the efficacy of multiple antigens. The company has an option to acquire exclusive, global rights to Javelin, an “antibody-guided antigen” delivery system.

PGT has a license agreement with a leading national-level poultry vaccine company for PGT to supply Hercules. A new vaccine will launch in 2016. PGT is in late stage development for a vaccine against the parasite Eimeria and expects to have a license agreement for this vaccine in 2016. In addition, Javelin is expected to be ready for out-licensing in 2017. A major focus for PGT is human food safety vaccines protective against Salmonella, E. coli & Campylobacter in poultry, cattle and swine. The first vaccine is in the regulatory stage and is expected to receive a USDA regulatory approval in 2018.

Key Advantages of PGT’s Vaccines & Adjuvant / Delivery Systems:

• Promote cross-protective immunity

• Are IgA, IgG & T cell targeted for mucosal & systemic immunity

• Are designed to be orally administered (although they can also be injected), providing substantial cost-savings in delivery and administration

• Are low cost to manufacture by simple fermentation

• Are part of a broad pipeline of Aegis vaccine candidates and adjuvant trials in poultry, swine, ruminants, and fish

• Are believed to be sufficiently stable and would not require a continuous cold chain for field use

• Have received validation from government and international partnerships with multiple collaborations, multiple regions addressing multiple animal health needs

One achievement in the Animal Health space:PGT’s Aegis vaccine platform was built on the hypothesis that highly conserved antigens can provide robust cross-protective immunity across strains and species of pathogens and parasites and be orally administered: this has now been demonstrated in multiple trials around the world in both live and inactivated (adjuvated) constructs.

Biggest opportunity in the Animal Health industry?Addressing animal health issues also related to human health including food safety pathogens, other human pathogens and parasites in livestock hosts, antibiotic resistance, and chemical residues in animal products, while at the same time continuing to improve animal welfare and productivity.

One thing we aim to change and/or improve the Animal Health industry? The flow of breakthrough science in genetics, immunology and molecular biology into animal health to create practical vaccine solutions to major problems in food production for the world’s rapidly expanding population.

Tim CollardCEO


About the Speaker:Tim Collard is the Chief Executive Officer of Pacific GeneTech. He studied biology at Bristol University in the U.K. and he has worked for 40 years in the pharmaceutical and biotechnology industries, mainly in Asia. After university Tim worked with Connaught Laboratories to supply vaccines to the Hong Kong government. He then joined Califas, a China-based consultancy, negotiating the first Sino-US joint manufacturing contract in the Chinese healthcare industry for a subsidiary of Squibb, and was later closely involved in preparatory work for the Shanghai Squibb pharmaceutical joint venture. In 1980, Tim joined Solvay as Far East Director for Solvay’s Biochem Products division, a JV with the Pasteur Institute. In 1987 he became General Manager, Far East, for Porton International, a biopharmaceuticals company associated with the Centre for Applied Microbiology and Research at Porton Down in England. He successfully established marketing, distribution and Asian R&D for these companies. Later, working as an independent consultant he built a marketing, distribution and Asian R&D network for Ecogen, a U.S. agricultural biotechnology company, and was also responsible for negotiating a “first mover” supply agreement for bulk antibiotics between a Chinese producer and a British veterinary pharmaceutical company. In 1993 he co-founded and was appointed Vice President of Lotus Healthcare Corporation, a manufacturer of oral medicinal narcotics in China. He was responsible for all aspects of the company’s business development, in-licensing and technology transfer, which included upgrading China’s production of bulk opiates. He joined Pacific GeneTech as its founder CEO in 2009.



DHN is a high-tech biotechnological enterprise that integrates its primary business of biological products, pharmaceutical preparation, and feed additives with its new business areas of marine industry and aquatic animal health medicines. DHN is designated by the Chinese Ministry of Agriculture (MOA) to produce highly-pathogenic avian influenza (AI) vaccines and highly pathogenic porcine reproductive and respiratory syndrome (PRRS) vaccines. DHN is also the global pioneer manufacturer of the live grass carp hemorrhage vaccine and the first producer of coccidiosis vaccines in Asia. DHN’s products not only cover every province and region in China, but are also exported to countries in South-East Asia and the Middle East (such as Indonesia, Vietnam and Egypt), gaining positive recognition and respect from international customers such as CP in Thailand, CPC Egypt, and VIDO Canada. Indeed, DHN’s products are gaining popularity everywhere and, in 2015, the annual sales reached approximately RMB 1.5 billion.

DHN has a professional R&D team with more than 100 scientists. DHN is certified as an Enterprise Key Laboratory of MOA for Animal Disease Prevention and Control, Biotechnology and Biological Product R&D, and set up the Guangdong Enterprises Key Laboratories of Technical Research and Application on Veterinary Biological Products, the Guangdong Engineering and Technological Research Center on Animal Health Products, the Guangdong Enterprise Workstations of Academics and Experts, and the South China Animal Diseases Inspection Center. In addition, DHN set up the Bio-safety Level III (BSL-3) Lab in collaboration with Sun Yat-Sen University which qualifies DHN to conduct research work on highly pathogenic avian influenza. DHN is a domestic leader in several advanced technologies, such as cell suspension culture technology in bioreactors, live carrier technology for the Marek’s disease virus, and antigen purification recycling technology.

In November 2015, “The production and application of virus buffer solution (ZL 2012 1 0049094.2)” won the China Outstanding Patent, which was issued by WIPO-SIPO. This patented technology was a breakthrough for virus purification and recycling for chick embryo allantoic fluid, resulting in significant improvements in antigen yield.

One achievement in the Animal Health space:DHN is an innovator in establishing a poultry biosecurity system for comprehensive disease control for large-scale livestock and poultry breeding farms, resulting in an Outstanding National Award. DHN has successfully licensed out a number of innovative vaccines, such as AI vaccines, PRRS vaccines, and the live grass carp hemorrhage vaccine.

Biggest opportunity in the Animal Health industry?More and more attention has been paid to animal health, public health and food safety. This requires more innovation in biotechnology to tackle various issues. This will also bring more opportunities to Chinese animal health companies.

One thing we aim to change and/or improve the Animal Health industry? To enhance international technical exchange and cooperation，and to accelerate the commercialization of new technology. All these will result in improvements in animal health, public health and food safety.

Ruiai ChenProfessor, President


About the Speaker:Dr. Ruiai Chen received her Ph.D. in Microbiology from the China Agricultural University. Currently she is a professor and Ph.D. advisor at the College of Veterinary Medicines, South China Agricultural University. Dr. Chen is President of Guangdong Wens Dahuanong Biotechnology Co., Ltd. (DHN), and Vice-Chairman of the China Veterinary Drug Association (CVDA). She is one of the most influential leaders in the Chinese animal health arena and, as a result, she is entitled to special allowances provided by the Chinese State Council, an honor for outstanding scientists in China. Dr. Chen is a well-known expert in the prevention and control of animal diseases, and vaccine research. She possesses 41 patents and 22 new veterinary drug certificates. Dr. Chen has received 14 technical awards at the provincial and national levels, such as first prize for the Guangdong Provincial Science and Technology Award and the China Outstanding Patent. Her achievements include the development and industrialization of avian influenza vaccines, PRRS vaccines and coccidiosis vaccines. These vaccines are now making great contributions to disease control in China, Southeast Asia (e.g., Indonesia), and Middle East countries. Dr. Chen is also director of the Enterprise Key Laboratory of MOA for Animal Disease Prevention and Control, Biotechnology and Biological Product R&D. She has contributed greatly to commercialization of technology for animal vaccine and pharmaceutical products.



EpiBiome is a precision microbiome engineering company surveilling bacterial populations and developing effective and sustainable FDA-approved therapies to combat infectious diseases in animal and human medicine without the use of antibiotics.

EpiPhany® Bacterial Profiling Service uses unique next-generation genomic sequencing and informatics technology to provide the most reproducible and accurate biogram -- the profile of bacteria present in a sample – available today. EpiPhany’s unique method is rapid, low cost, and produces unprecedented levels of discrimination among strains of bacteria. EpiPhany® provides the highest level speciation possible – optimally to the genus and species level, depending on the organisms present in the sample – using information that is natively present in the 16S ribosomal RNA gene in a sample. This information may be applied for many purposes across numerous segments of animal health.

EpiBiome’s bacteriophage-based process integrates world-class expertise in microbiology, phage biology and next-generation sequencing in one solutions-driven platform. EpiBiome deploys bacteriophages, naturally occurring bacteria-specific viruses, to address problematic bacteria. The company is working to develop FDA-approved therapies to prevent and treat infection in animal agriculture and in humans. EpiBiome has developed partnerships and collaborations in order to access specimens from animals and humans affected by bacterial infections, such as specimens collected from cows with mastitis (infection of the udder). The company uses a proprietary sequencing platform to identify the likely infection-causing bacteria. Once identified, the bacteria are selectively cultured and fully sequenced. In parallel, EpiBiome is developing a collection of sequenced and well characterized bacteriophages. The bacteria are co-cultured with the bacteriophages to isolate the “matching” phages able to kill the bacteria. Once isolated, the phages are combined according to proprietary methods to create a cocktail that kills the harmful bacteria present and prevents the emergence of bacterial resistance. The company’s first target is effective treatment for mastitis in dairy cattle.

People and animals globally benefit from reduced disease, better food and water quality, enhance humanitarian care for the developing world and for animals, and more effective, less toxic treatments for diseases we can’t prevent. EpiBiome’s mission to surveil pathogenic bacteria and to develop FDA-approved alternatives to the use of antibiotics used in both human and animal medicine means that the antibiotics that are effective today have a better chance of continuing to be effective long into the future.

One achievement in the Animal Health space:EpiBiome demonstrated proof of concept utilizing bacteriophage therapy in lactating cows infected with a persistent strain of E. coli. Treated cows had a 2 log reduction over untreated cows, a statistically significant effect. Moreover, treated cows showed faster elimination of E. coli than untreated cows.

Biggest opportunity in the Animal Health industry?One of the biggest opportunities in the animal health industry is addressing the growing global threat of antimicrobial resistance through the development of antimicrobial alternatives and leveraging next generation gene sequencing to understand the emergence of antimicrobial resistance.

One thing we aim to change and/or improve the Animal Health industry? EpiBiome’s technologies to surveil pathogenic bacteria and develop FDA-approved alternatives to antibiotics will allow animals to benefit from reduced disease, better feed and water quality, enhanced care, and more effective, less toxic treatments for non-preventable diseases. EpiBiome’s processes will allow today’s effective antibiotics a better chance of continued future effectiveness.

Heather J. BessoffDVM


About the Speaker:Dr. Heather Bessoff is the Director of Sales, Marketing and Business Development for EpiBiome, Inc. where she is leading partner relations, and strategic development and commercialization of new products. Dr. Bessoff was a practicing and global consulting veterinarian with a specialty in dairy herd performance medicine and provided consulting services for private equity firms, venture capitalists and new businesses interested in animal health and new technology. Heather started her career in dairy practice in Wisconsin, USA before moving into global herd management consulting for ABS Global, Inc. – a bovine genetics company – and her own practice, Dairy Management Solutions. Dr. Bessoff transitioned into industry in both animal and human research and development, new products marketing and operations, taking on roles of increasing responsibility in the strategic development and commercialization of products, portfolios and new businesses for Pfizer, Inc. and Elanco Animal Health. Dr. Bessoff is a graduate of the University of Connecticut College of Agriculture and Natural Resources and University of Wisconsin School of Veterinary Medicine. She is an active member of American Veterinary Medical Association, American Association of Bovine Practitioners, and local, national and international industry associations.

EpiBiome is a precision microbiome engineering company surveilling bacterial populations and developing effective and sustainable FDA-approved therapies to combat infectious diseases in animal and human medicine without the use of antibiotics.



ViroVet is a pioneering company dedicated to the development of disruptive and innovative technologies for the control of viral diseases in livestock, with antiviral drugs for respiratory disease complexes and innovative vaccines for viral infections in swine leading the pipeline. The livestock industry is a 100+ billion-euro industry. Viral diseases cost producers billions every year in losses and threaten the world supply of animal protein.

The strategy of ViroVet is to provide novel solutions to be used alone or in combination with vaccines and biosecurity measures in order to provide livestock producers, national governments and international organizations with a multi-faceted arsenal of virus control weapons against endemic and epizootic viral diseases.

It is clear that with the growing world population there is an increased demand for more protein-rich diets. With the increasing density of the livestock industry, the intensifying global trade and climate changes, there is an ever increased risk for the global spread of viral diseases, severely damaging livestock industry.

ViroVet has already enlisted the support of a number of key opinion leaders (KOLs) in livestock medicine confirming the extensive market for antiviral drugs and novel vaccines addressing the challenges of spreading viral diseases. KOLs feel that ViroVet’s products have the potential to reduce the use of antibiotics and revolutionize the livestock industry worldwide.

One achievement in the Animal Health space:Our team has brought Okapi Sciences from a series A in 2008 to a healthy acquisition in 2014. The same team has now merged Okapi Sciences’ livestock assets with innovations at Academia to form ViroVet, a company that was elected as 2015 startup of the year by Animal Pharm News.

Biggest opportunity in the Animal Health industry?Viral diseases cost producers as well as governments more than 10 billion USD every year in losses, threatening the world supply of animal protein and causing massive antibiotic use. There is a clear need for better vaccines and fast acting antiviral drugs to regain control over viral diseases in Livestock and cut antibiotic use.

One thing we aim to change and/or improve the Animal Health industry? We want producers and national governments soon to be able to “act now” using our fast acting and broadly active antiviral drugs but also to “act long” by providing them with more efficacious, more affordable and thermostable vaccines to fight and prevent endemic and epizootic viral diseases in livestock.

Dr. Erwin Blomsmaco-founder and Chief Executive Officer

“Viral diseases cost producers as well as governments more than 10 billion USD every year in losses, threatening the world supply of animal protein and

causing massive antibiotic use. There is a clear need for better vaccines and fast acting antiviral drugs…


About the Speaker:Erwin Blomsma holds a Master’s degree in Bioscience Engineering and a Ph.D. in Applied Biological Sciences (1995) from KU Leuven in Belgium. After post-doctoral studies at UCB he started his career at Janssen Pharmaceutica in 1996 with a focus on assessing and implementing new technologies. In 2000 he co-founded Crystallics, a spin-off from the University of Leiden (NL) specializing in preformulation research. Crystallics was absorbed by Avantium Technologies in 2001, and he was appointed Chief Operating Officer there in 2004, playing a key role in making the company cash-positive. In 2007, Dr Blomsma joined Dr Stefaan Wera and Professor Johan Neyts as co-founder and CEO of Okapi Sciences and after a series A of 8.5 million EUR end of 2008 the team developed a pipeline of 7 products (2 in pivotal clinical trials) and signed a license deal with Novartis Animal Health in 2013. Okapi Sciences was then acquired by Aratana Therapeutics for 44 million USD in January 2014. From the acquisition to August 2015 he was the General Manager of Aratana Therapeutics NV in Belgium and Vice President of Aratana Therapeutics, Inc. In July 2015 he joined Aratana Therapeutics NV, Stefaan Wera BVBA and Nesya Goris as co-founder of ViroVet BVBA. In August 2015, Erwin Blomsma resigned at Aratana Therapeutics to become an independent advisor to Aratana Therapeutics and CEO at ViroVet and now focuses on signing a first collaborative R&D deal with a large animal health company and the closing of a series A investment round. Furthermore, Erwin Blomsma is the current Chairman of FlandersBio, a cluster organization representing over 330 life sciences companies in Flanders, Belgium.



21-23rd February 2017, London, UK www.animalhealthevent.com

Contact Us Today at [email protected] or Call Us at +44 (0)20 3696 2920. Sarah Clayton

Managing Director Kim Vigilia

COO Stephen Swarray

Director of Commercial Partnerships

European Animal Health Investment Forum

Emerging Company Showcase

Registration is now Open

Submit Now!

We’d like to thank our 2017 partners

Farbe/colour:PANTONE 288 CV

Headline Sponsor:

Event Sponsors:

Interested in Brand Solution Opportunities?

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.With our extensive marketing experience and strategy, your partnership with the conference will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. Ask us about the different ways you can get involved. Contact Stephen Swarray to find out more about each package by emailing at [email protected] or by calling +44 (0)20 3696 2920.

Submission for the 2017 European Emerging Company Showcase is now open through the 16th December

Can’t join us in Hong Kong?

http://animalhealthevent.com/register/pricing

http://animalhealthevent.com/emerging-company-showcase-submission

emerging animal health company apac showcase: presenter ...€¦ · company apac showcase:...

Documents